Table 2 Clinico-pathological characteristics
Local/regional recurrence cohort (n = 41) | n (%) |
|---|---|
Age, median (range) | 51 (27–84) |
Subtypes | Â |
 ER+/HER2− | 23 (56%) |
 ER+/HER2+ | 6 (15%) |
 ER+/HER2 unknown | 12 (29%) |
T stage at diagnosis | |
 T1 | 25 (61%) |
 T2 | 13 (32%) |
 T3 | 1 (2%) |
 T4 | 1 (2%) |
LN+ at diagnosis | 17 (41%) |
Neoadjuvant endocrine treatment | 2 (5%) |
Endocrine treatments pre-biopsy | |
 Tamoxifen only | 23 (56%) |
 Aromatase inhibitors (AI) | 5 (12%) |
 Tamoxifen + AI | 13 (32%) |
Adjuvant/NAT chemotherapy | |
 Adjuvant | 16 (39%) |
 Neoadjuvant | 10 (24%) |
Local/regional recurrence type | |
 Local recurrence | 22 (54%) |
 Regional recurrence | 19 (46%) |
 Unknown | 1 (2%) |
Distant recurrence | 12 (29%) |
Median follow-up time from diagnosis, years (range) | 12 (4–24) |
Median follow-up time from first local recurrence, years (range) | 5 (0–20) |
Median follow-up time from tested local recurrence, years (range) | 4 (0–17) |